IP Library Granted Patent US 8,623,915
Granted Patent B2
US 8,623,915 · App. 13/650,852 · Granted Jan 7, 2014

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

Inventors: Jean-Louis Henri Dasseux (Toulouse, FR); Carmen Daniela Oniciu (Toulouse, FR)
Assignee: Esperion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,623,915
App. No.
13/650,852
Granted
Jan 7, 2014
Kind
B2
Abstract

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (36)

1. A method for treating or preventing dyslipidemia, dyslipoproteinemia, metabolic syndrome or Syndrome X, in a patient in need of such treatment or prevention, comprising administering to the patient a therapeutically or prophylactically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 0 to 5;

(b) each occurrence of n is independently an integer ranging from 3 to 7;

(c) X is (CH 2 ) z or Ph; wherein z is an integer from 0 to 4;

(d) each occurrence of R 1 and R 2 is independently (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, phenyl, benzyl, or R 1 and R 2 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloalkyl group;

(e) each occurrence of R 11 and R 12 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloalkyl group;

(f) each occurrence of Y 1 and Y 2 is independently (C 1 -C 6 )alkyl, OH, COOH, COOR 3 , SO 3 H,

wherein:

(i) R 3 is (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C 1 -C 6 )alkoxy, or phenyl groups,

(ii) each occurrence of R 4 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C 2 -C 6 )alkynyl and is unsubstituted or substituted with one or two halo, OH, C 1 -C 6 alkoxy, or phenyl groups; and

(iii) each occurrence of R 5 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C2-C6)alkynyl.

2. The method of claim 1 , wherein each occurrence of Y 1 and Y 2 is independently OH, COOR 3 , or COOH.

3. The method of claim 1 , wherein m is 0.

4. The method of claim 1 , wherein m is 1.

5. The method of claim 1 , wherein n is 4.

6. The method of claim 1 , wherein n is 5.

7. The method of claim 1 , wherein X is (CH 2 ) z and z is 0.

8. The method of claim 1 , wherein each occurrence of R 1 and R 2 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloalkyl group.

9. The method of claim 1 , wherein the compound of formula I is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound of formula I is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 wherein the compound of formula I is

12. The method of claim 1 wherein the compound of formula I is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 wherein the compound of formula I is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 wherein the compound of formula I is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 1 , wherein the method comprises treating or preventing dyslipidemia and said dyslipidemia is hypertriglyceridemia.

16. The method of claim 10 , wherein the method comprises treating or preventing dyslipidemia and said dyslipidemia is hypertriglyceridemia.

17. The method of claim 1 , wherein the method comprises treating or preventing dyslipoproteinemia.

18. The method of claim 1 , wherein the method comprises treating or preventing metabolic syndrome or Syndrome X.

19. The method of claim 10 , wherein the method comprises treating or preventing dyslipoproteinemia.

20. The method of claim 10 , wherein the method comprises treating or preventing metabolic syndrome or Syndrome X.

Assignments (2)
MERGER Recorded Oct 14, 2014
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033946/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2013
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 030474/0010 →
Continuity (7)
Continuation 13414855 · Mar 8, 2012
Continuation 13270297 · Oct 11, 2011
Continuation 12135504 · Jun 9, 2008
Continuation 11426380 · Jun 26, 2006
Division 10743287 · Dec 23, 2003
Provisional Application 60441795 · Jan 23, 2003
Related Publication 20130040916A1 · Feb 14, 2013